Skip to content
AP Psychology · Biological Bases of Behavior

Alzheimers disease

Alzheimers disease appears in 3 reviewed AP Psychology questions and sits in Biological Bases of Behavior. Below are worked examples showing exactly how the exam tests it, with the answer marked and every distractor explained.

Alzheimer's disease is a brain disorder that slowly destroys memory and thinking. It involves the loss of neurons that make acetylcholine, along with plaques and tangles that damage brain tissue, including the hippocampus.

Why it matters

It is the standard example of a disorder tied to acetylcholine loss, just as Parkinson's is tied to dopamine loss. Losing ACh-producing neurons is one feature of the disease, alongside plaques, tangles and widespread neuron loss. It also connects brain structure (hippocampus) to memory loss.

How the exam tests it

Questions pair it with acetylcholine and ask how a treatment works. Cholinesterase inhibitors such as donepezil block the enzyme that breaks down ACh, which can modestly improve memory.

Don’t confuse it with

Students mix it up with Parkinson's disease, which comes from the loss of dopamine neurons and mainly affects movement, not memory.

Alzheimers disease in real questions

Example 1Harder
A patient with Alzheimer's disease is found to have reduced acetylcholine (ACh) in the brain. A treatment that prevents the breakdown of acetylcholine in the synapse would be classified as which type of drug?
  1. AA MAOI, because monoamine oxidase degrades acetylcholine in the synapse, so blocking that enzyme would increase ACh levels
  2. BA cholinesterase inhibitor, because it blocks the enzyme that breaks down ACh, increasing ACh availabilityCorrect
  3. CA dopamine antagonist, because it prevents dopamine from binding to its receptor and allows acetylcholine to compensate
  4. DAn ACh reuptake inhibitor, because it prevents the presynaptic reabsorption of ACh, leaving more in the synaptic cleft

Why B is right

Acetylcholinesterase is the enzyme that breaks down acetylcholine in the synaptic cleft. Cholinesterase inhibitors (like donepezil/Aricept, rivastigmine) block this enzyme, preventing ACh degradation and leaving more ACh available to bind to receptors. This temporarily improves cholinergic transmission and can modestly improve memory and cognitive function in Alzheimer's patients. They are among the most common pharmacological treatments for Alzheimer's disease.
Why the other 3 choices miss
A
Incorrect because MAO (monoamine oxidase) specifically degrades monoamine neurotransmitters (dopamine, serotonin, norepinephrine), not acetylcholine; MAOIs would not increase ACh levels; the enzyme that breaks down ACh is acetylcholinesterase.
C
Incorrect because dopamine antagonists block dopamine receptors; they have no direct effect on acetylcholine levels and are not used to treat Alzheimer's disease (which involves acetylcholine deficiency, not dopamine excess).
D
Incorrect because there is no clinically established acetylcholine reuptake inhibitor used in the way that SSRIs block serotonin reuptake; acetylcholine clearance from the synapse is primarily accomplished by enzymatic degradation (by acetylcholinesterase), not by reuptake transporters; the correct treatment approach is to block the enzyme.

Studied alongside

Other concepts from Biological Bases of Behavior.